REM-422, a First-in-Class Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity as Monotherapy and in Combination in Preclinical Models of AML WATERTOWN, Mass., November 20, 2024 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced an upcoming oral presentation […]